




# Laboratory Confirmation of Human Cases of Botulism

Susan E. Maslanka, PhD

National Botulism Laboratory Preparedness Team  
Division of Foodborne, Bacterial and Mycotic Diseases  
National Center for Zoonotic, Vectorborne, and Enteric Diseases



## National Botulism Laboratory Preparedness Team DFBMD/NCZVED



Maintaining US Scientific Expertise for Laboratory Confirmation of Botulism Through Outbreak Investigations and Research



# Botulinum toxin types

- Seven known toxins:A,B,C,D,E,F,G
  - Human botulism
    - A, B, E, F (C & D were described in late 1950's)
  - Animal
    - B, C, D, E
  - Natural disease unidentified
    - Type G




# Neurotoxigenic *Clostridia*, sp

- *Clostridium botulinum*
- *C. baratii* type F
- *C. butyricum* type E



# Botulism Types-


Foodborne




Infant  
(& adult colonization)



Wound



## U.S. LABORATORY-CONFIRMED BOTULISM, 2000-2005



# Global Disease

North America  
USA & Canada

South America  
Argentina & Brazil

Western Europe  
UK, France & Italy

Central Europe  
Poland & Germany

Eastern Europe  
Russia & Ukraine

Southwestern Europe  
Georgia & Spain

Southeastern Europe  
Armenia & Romania



Prevalent on all continents

Northern Europe  
Denmark & Finland

Southern Europe  
Italy

Asia  
China, Japan, Thailand

Middle East  
Iran & Saudi Arabia

Africa  
Egypt & Ethiopia

Oceania  
Australia




## Toxin Type of Foodborne Outbreaks

Region	Predominate Toxin type
North/South America	A (vegetables); E (fish)
Europe	B (meat in Germany, Belgium, Poland); B (vegetables in Italy, Spain)
Scandinavia	E (fish)
Soviet Union	E (fish); A (vegetables)
Asia	A (plant material); E (fish)



# Fatality Rate



SAFER • HEALTHIER • PEOPLE™

## Acceptable Specimens

(from patients exhibiting symptoms consistent with the diagnosis of botulism, only)

Foodborne	Infant	Wound
serum, gastric, vomitus, stool, sterile water enema, food samples	serum, stool, rectal swabs, potential sources	serum, stool (in case not wound), tissue

All specimens should be maintained at 4 C, not frozen

SAFER • HEALTHIER • PEOPLE™



# Mouse Bioassay

## Advantages


- Exquisitely sensitive ( $10 \times 10^{-12}$  grams = 0.000000000010 g)

## Disadvantages

- Hazardous
- Extensive animal use
- Only 17 test sites around the country (14 state, 2 local, CDC)

CHRONIC DISEASE PREVENTION • INFECTIOUS DISEASE PROTECTION • IMMUNIZATION • INJURY PREVENTION • PEDIATRIC HEALTH • GLOBAL PARTNERSHIPS • MINORITY OUTREACH • MONITORING HEALTH • COMMUNITY PARTNERSHIPS  
**SAFER • HEALTHIER • PEOPLE™**  
HEALTH EDUCATION • EPIDEMIOLOGY • WORKPLACE HEALTH • IMMUNIZATION • WORKPLACE SAFETY • TRAINING • HEALTH PREVENTION RESEARCH • PRIVATE SECTOR PARTNERSHIPS • PUBLIC HEALTH WORKFORCE • WOMEN'S HEALTH

## Sample Processing for the Mouse Bioassay



# Requirements for Toxin Potency in the Clinical Laboratory

- Determination of level of toxin in contaminated food source
- Determination of level of toxin in circulation of exposed patients
- Determination of level of toxin produced by isolated outbreak strain (s)



## Impact on Animal Use



A single specimen



# Botulinum Toxin ELISA ABEF


- National testing capacity increased by 85%
- Time to detection reduced by 44%
- Sample throughput increased 67%
- Detects < 1 mouse lethal dose
- Test ruggedness: all reagents provided and quality controlled



The Botulinum Toxin Type A, B, E, or F ELISA Kits

SAFER • HEALTHIER • PEOPLE™  
Rapid Toxin Detection and Identification

## Real-time Polymerase Chain Reaction (PCR) (A-G)




### Impact on Preparedness

- Laboratory testing algorithm streamlined
- Time-to-identification reduced 5-15 days
- Response within 1<sup>st</sup> 24 hrs improved
- Reduced animal use

Identification of toxin DNA  
in 0.3- 1.5 hr

SAFER • HEALTHIER • PEOPLE™  
Rapid Detection and Identification of Organism


# MS Background: Intracellular Targets



SAFER • HEALTHIER • PEOPLE™  
 The seven different serotypes of BoNT target different SNARE proteins and/or protein sites.  
 Cleavage of any one of these proteins prevents complex formation needed for acetyl choline release.

## MS Botulinum A cleavage products

Cartoon representation of test



SAFER • HEALTHIER • PEOPLE™  
 CHRONIC DISEASE PREVENTION • INFECTIOUS DISEASE PROTECTION • IMMUNIZATION • INJURY PREVENTION • PEDIATRIC HEALTH • GLOBAL PARTNERSHIPS • MINORITY OUTREACH • MONITORING HEALTH • COMMUNITY PARTNERSHIPS • HEALTH EDUCATION • EPIDEMIOLOGY • WORKPLACE HEALTH • IMMUNIZATION • WORKPLACE SAFETY • TRAINING • HEALTH PREVENTION RESEARCH • PRIVATE SECTOR PARTNERSHIPS • PUBLIC HEALTH WORKFORCE • WOMEN'S HEALTH

Test	Strengths	Limitations
Mouse	Sensitive, active toxin, all toxin types, subtypes, and unidentified, can direct treatment	Limited US capacity, can take up to 4 days; nonspecific death occurs occasionally
ELISA	Sensitive, rapid (~4.5 hrs), can be deployed to many laboratories CDC ELISA detects all known subtypes of toxin A and B	Limited to 4 toxin types, may be insensitive to some toxin subtypes, may give false positives, matrix effects
MS	Sensitive, rapid (15 min to overnight), can be automated	Limited to known toxin types, may be insensitive to toxin subtypes, expensive, matrix effects unknown
PCR	Rapid Identification of organism	Cannot predict toxin production, matrix effects unknown

**SAFER • HEALTHIER • PEOPLE™**  
 HEALTH EDUCATION • EPIDEMIOLOGY • WORKPLACE HEALTH • IMMUNIZATION • WORKPLACE SAFETY • TRAINING • C  
 LTH • PREVENTION RESEARCH • PRIVATE SECTOR PARTNERSHIPS • PUBLIC HEALTH WORKFORCE • WOMEN'S HEALTH



## Challenges to In vitro Testing for Human Cases of Botulism



- 7 toxin types with unknown number of subtypes
- Numerous specimen matrices
- Low toxin levels in clinical specimens
- Regulatory issues for testing clinical specimens-  
in vitro device
- Regulatory issues for testing commercial  
products– FDA/USDA requirements
- Test availability

**SAFER • HEALTHIER • PEOPLE™**  
 HEALTH EDUCATION • EPIDEMIOLOGY • WORKPLACE HEALTH • IMMUNIZATION • WORKPLACE SAFETY • TRAINING • C  
 LTH • PREVENTION RESEARCH • PRIVATE SECTOR PARTNERSHIPS • PUBLIC HEALTH WORKFORCE • WOMEN'S HEALTH